Welcome!

News Feed Item

PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_us_drug_forecast_market_analysis_2022.html

PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022

Summary

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

However, these classes represent the crowded, saturated, generic portion of the US atopic dermatitis market, with little room for innovative products. That said, the reliance on these agents will lead to an overall steady growth over the 10-year forecast period, with respective CAGRs of 1.2% and 0.5% for corticosteroids and moisturizers/emollients during this timeframe.

Scope

- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Atopic Dermatitis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.2 Symptoms 18
4 Disease Management 20
4.1 Diagnosis 20
4.2 Treatment Overview 22
4.3 US 28
4.3.1 Diagnosis 28
4.3.2 Clinical Practice 30
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 34
5.3 Product Profiles - Major Brands 35
5.3.1 Protopic (tacrolimus) 35
5.3.2 Elidel 42
5.3.3 Cyclosporine (numerous generic names) 47
5.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis 50
5.4 Product Profiles - Off-Label Therapies 52
5.4.1 Actimmune (interferon gamma-1b) 52
6 Opportunity and Unmet Need 56
6.1 Overview 56
6.2 Unmet Needs 57
6.2.1 A Systemic Drug for Severe Recalcitrant Patients 57
6.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 59
6.2.3 A Drug that Effectively Controls Patients' Pruritus 60
6.2.4 Further Research into the Pathophysiology of Atopic Dermatitis 61
6.2.5 A Drug that Induces Disease Remission 62
6.2.6 Improved Quality of Life for Both Patients and their Carers 63
6.3 Unmet Needs Gap Analysis 63
6.4 Opportunities 65
6.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients 65
6.4.2 Predictive Tests for Patient Stratification 65
6.4.3 More Therapeutic Options that Address Patients' Pruritus 66
7 Pipeline Assessment 67
7.1 Overview 67
7.2 Promising Drugs in Clinical Development 69
7.2.1 Dupilumab (SAR231893/ REGN668) 70
7.2.2 AN2728 80
7.2.3 Phase II Pipeline Products 88
8 Market Outlook 89
8.1 Global Drivers and Barriers 89
8.1.1 Driver: Anticipated launch of the first biologic for the treatment of moderate to severe disease 89
8.1.2 Driver: The underserved severe refractory patient segment presents an untapped market opportunity 90
8.1.3 Driver: A drug that is able to target two or more atopic diseases would gain a foothold in these markets 90
8.1.4 Driver: Atopic dermatitis presents an attractive patient population for drug developers 90
8.1.5 Driver: Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents 91
8.1.6 Barrier: First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market 92
8.1.7 Barrier: The largest atopic dermatitis patient segment - mild disease - can be well-controlled on most forms of topical therapy 92
8.1.8 Barrier: Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products 92
8.1.9 Barrier: The complexity of the multiple etiologies that lead to atopic dermatitis means that treatment outcomes with existing drugs are not universal across all patient groups 93
8.1.10 Barrier: A significant proportion of patients experience disease remission in their early adolescent years and this may occur without drug therapy 94
8.2 US 94
8.2.1 Forecast 94
8.2.2 Key Events 97
8.2.3 Drivers and Barriers 98
9 Appendix 101
9.1 Bibliography 101
9.2 Abbreviations 107
9.3 Methodology 109
9.4 Forecasting Methodology 109
9.4.1 Diagnosed Atopic Dermatitis Patients 109
9.4.2 Percent Drug-treated Patients 110
9.4.3 Drugs Included in Each Therapeutic Class 110
9.4.4 Launch and Patent Expiry Dates 110
9.4.5 General Pricing Assumptions 111
9.4.6 Individual Drug Assumptions 112
9.4.7 Generic Erosion 114
9.4.8 Pricing of Pipeline Agents 114
9.5 Physicians and Specialists Included in this Study 115
9.6 Primary Research - Prescriber Survey 116
9.7 About the Authors 117
9.7.1 Author 117
9.7.2 Global Head of Healthcare 118
9.8 About GlobalData 119
9.9 Disclaimer 119

1.1 List of Tables

Table 1: Symptoms of Atopic Dermatitis 19
Table 2: Treatment Guidelines for Atopic Dermatitis 25
Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013 27
Table 4: Referral Rates to a US Dermatologist, Split by Severity and Specialist Type, 2013 29
Table 5: Key Metrics Relating to the Diagnosis, Relapse and Remission Rates of Atopic Dermatitis in the US, 2013 30
Table 6: Leading Treatments for Atopic Dermatitis, 2013 35
Table 7: Product Profile - Protopic 37
Table 8: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients 38
Table 9: Protopic SWOT Analysis, 2013 41
Table 10: Product Profile - Elidel 43
Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies 44
Table 12: Elidel SWOT Analysis, 2013 46
Table 13: Product Profile - Cyclosporine 48
Table 14: Cyclosporine SWOT Analysis, 2013 50
Table 15: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2013 51
Table 16: Product Profile - Actimmune 53
Table 17: Actimmune SWOT Analysis, 2013 55
Table 18: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment 57
Table 19: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013 64
Table 20: Late-Stage Atopic Dermatitis Pipeline, 2013 69
Table 21: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013 70
Table 22: Product Profile - Dupilumab 72
Table 23: Ongoing Clinical Trials of Dupilumab in Atopic Dermatitis Patients, as of September 2013 74
Table 24: Dupilumab SWOT Analysis, 2013 79
Table 25: Product Profile - AN2728 81
Table 26: Efficacy Results for AN2728 in Mild to Moderate Adolescent Atopic Dermatitis Patients (Day 29) 82
Table 27: AN2728 SWOT Analysis, 2013 87
Table 28: Phase II and Phase I Atopic Dermatitis Pipeline, 2013 88
Table 29: Global Atopic Dermatitis Market - Drivers and Barriers, 2012-2022 89
Table 30: Sales Forecasts ($m) for Atopic Dermatitis in the US, 2012-2022 96
Table 31: Key Events Impacting Sales for Atopic Dermatitis in the US, 2012-2022 97
Table 32: Atopic Dermatitis Market in the US - Drivers and Barriers, 2012-2022 98
Table 33: Key Launch Dates 110
Table 34: Key Patent Expiries 110
Table 35: Physicians Surveyed, By Country 116

1.2 List of Figures

Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin 16
Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis 23
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2012-2022 69
Figure 4: Sales for Atopic Dermatitis in the US by Drug Class, 2012-2022 97


Read the full report:
PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_us_drug_forecast_market_analysis_2022.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.